Walder Wyss with the investors on Mosanna’s funding round
Walder Wyss advised the investors in Mosanna Therapeutics’ Series A financing round
EQT Life Sciences and Pivotal bioVenture Partners led the round in question, along with Forbion, Broadview Ventures and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures as well as Supermoon Capital and High-Tech Gründerfonds (HTGF).
The company
Headquartered in Basel, Switzerland, Mosanna Therapeutics’ is a clinical-stage biotech company, active in the development of an easy-to-use nighttime nasal spray to treat obstructive sleep apnea (OSA).
The Walder Wyss team
Partner Robert von Rosen (corporate/M&A and venture capital, pictured) led the Walder Wyss team on the matter, with further support from partner Alexander Gutmans (corporate/M&A and venture capital), managing associate Karina Tschon (corporate/M&A and venture capital), managing associate Michelle Bruni (tax), senior associate Simon Olstein (corporate/M&A), associate Oerjan Wickart (corporate/M&A) and associate Dario Glauser (employment).
